

LYNN SAGE BREAST CANCER FOUNDATION
FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2023 AND 2022
(With Independent Auditors' Report)

LYNN SAGE BREAST CANCER FOUNDATION

TABLE OF CONTENTS

DECEMBER 31, 2023

	<u>Pages</u>
INDEPENDENT AUDITORS' REPORT	1-3
FINANCIAL STATEMENTS:	
Statement of Financial Position	4
Statement of Activities	5
Statement of Functional Expenses	6
Statement of Cash Flows	7
NOTES TO FINANCIAL STATEMENTS	8-16



INDEPENDENT AUDITORS' REPORT

Board of Directors
Lynn Sage Breast Cancer Foundation
Chicago, Illinois

Opinion

We have audited the accompanying financial statements of Lynn Sage Breast Cancer Foundation, which comprise the statements of financial position as of December 31, 2023 and 2022, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Lynn Sage Breast Cancer as of December 31, 2023 and 2022, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Lynn Sage Breast Cancer Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Prior Year Financial Information

The comparative financial information of Lynn Sage Breast Cancer Foundation presented herein as of and for the year ended December 31, 2022, was derived from financial statements audited by other auditors, whose report dated September 13, 2023, expressed an unmodified opinion on those statements.

ICL, LLC

ICL, LLC
Chicago, IL

June 14, 2024

LYNN SAGE BREAST CANCER FOUNDATION

STATEMENTS OF FINANCIAL POSITION

DECEMBER 31, 2023 AND 2022

	<u>2023</u>	<u>2022</u>
<u>ASSETS</u>		
Cash and cash equivalents	\$ 1,223,393	\$ 1,462,277
Certificate of deposit	207,535	201,875
Investments	4,948,460	3,854,947
Contributions receivable	65,376	-
Prepaid expenses and other	14,911	875
	<u> </u>	<u> </u>
Total assets	<u>\$ 6,459,675</u>	<u>\$ 5,519,974</u>
 <u>LIABILITIES AND NET ASSETS</u>		
Liabilities:		
Grants payable	\$ 200,000	\$ 300,000
Accounts payable	15,856	-
	<u> </u>	<u> </u>
Total liabilities	<u>215,856</u>	<u>300,000</u>
Net Assets:		
Net assets without donor restrictions	<u>6,243,819</u>	<u>5,219,974</u>
Total net assets	<u>6,243,819</u>	<u>5,219,974</u>
	<u> </u>	<u> </u>
Total liabilities and net assets	<u>\$ 6,459,675</u>	<u>\$ 5,519,974</u>

See accompanying notes to the financial statements.

LYNN SAGE BREAST CANCER FOUNDATION

STATEMENTS OF ACTIVITIES

YEARS ENDED DECEMBER 31, 2023 AND 2022

	<u>2023</u>	<u>2022</u>
REVENUE AND SUPPORT:		
Individual and corporate contributions	\$ 838,787	\$ 907,696
Special events	1,492,888	224,359
Investments return, net	591,662	(436,982)
Donated goods and services	58,865	5,675
Total Revenue and Support	<u>2,982,202</u>	<u>700,748</u>
EXPENSES:		
Program services	1,051,083	1,197,146
Management and general	349,985	210,376
Fundraising	557,289	172,189
Total Expenses	<u>1,958,357</u>	<u>1,579,711</u>
CHANGE IN NET ASSETS	1,023,845	(878,963)
NET ASSETS, BEGINNING OF YEAR	<u>5,219,974</u>	<u>6,098,937</u>
NET ASSETS, END OF YEAR	<u>\$ 6,243,819</u>	<u>\$ 5,219,974</u>

See accompanying notes to the financial statements.

LYNN SAGE BREAST CANCER FOUNDATION

STATEMENTS OF FUNCTIONAL EXPENSES

YEARS ENDED DECEMBER 31, 2023 AND 2022

	2023				2022			
	Program Services	Management and General	Fundraising	Total	Program Services	Management and General	Fundraising	Total
Salaries and wages	\$ 36,340	\$ 163,529	\$ 163,529	\$ 363,397	\$ -	\$ 55,230	\$ 78,732	\$ 133,962
Payroll taxes	2,230	10,036	10,036	22,303	-	4,201	6,046	10,247
Employee benefits	-	-	-	-	-	2,646	4,549	7,195
Contractual services	-	13,513	4,048	17,561	-	-	-	-
Professional fees	-	102,814	-	102,814	-	114,936	3,675	118,611
Grants and donations	1,012,513	-	-	1,012,513	1,189,740	-	-	1,189,740
Public relations and media	-	-	65,508	65,508	-	-	1,921	1,921
Special event direct costs	-	-	304,673	304,673	-	-	38,749	38,749
Food and beverage	-	-	-	-	-	3,244	-	3,244
Gifts and awards	-	-	6,071	6,071	-	98	5,045	5,143
Meetings	-	7,905	-	7,905	-	320	-	320
Rent and storage	-	26,526	-	26,526	-	9,000	-	9,000
Website	-	-	-	-	7,406	4,937	12,343	24,686
Travel	-	150	-	150	-	-	-	-
Insurance	-	22,549	-	22,549	-	4,690	-	4,690
Office and supplies	-	194	-	194	-	492	456	948
Postage	-	773	-	773	-	473	334	807
Printing	-	1,491	3,424	4,915	-	365	1,197	1,562
Information technology	-	-	-	-	-	4,598	-	4,598
Bank charges and credit card fees	-	505	-	505	-	5,146	19,142	24,288
	<u>\$ 1,051,083</u>	<u>\$ 349,985</u>	<u>\$ 557,289</u>	<u>\$ 1,958,357</u>	<u>\$ 1,197,146</u>	<u>\$ 210,376</u>	<u>\$ 172,189</u>	<u>\$ 1,579,711</u>

See accompanying notes to the financial statements.

LYNN SAGE BREAST CANCER FOUNDATION

STATEMENTS OF CASH FLOWS

YEARS ENDED DECEMBER 31, 2023 AND 2022

	<u>2023</u>	<u>2022</u>
Cash Flows From Operating Activities:		
Change in net assets	\$ 1,023,845	\$ (878,963)
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Net realized and unrealized losses (gains) on investments	(479,048)	537,763
Donated stock	-	(5,131)
Proceeds from sale of donated stock	-	5,093
Change in assets and liabilities:		
Contributions receivable	(65,376)	20,000
Prepaid expenses and other assets	(14,036)	-
Grants payable	(100,000)	200,000
Accounts payable	15,856	(3,200)
Net cash provided by (used in) operating activities	<u>381,241</u>	<u>(124,438)</u>
Cash Flows From Investing Activities:		
Purchases of certificates of deposit	(5,660)	-
Purchases of investments	(1,664,163)	(1,002,127)
Proceeds from sales and redemptions of investments	1,049,698	896,457
Net cash used in investing activities	<u>(620,125)</u>	<u>(105,670)</u>
Cash Flows From Financing Activities:	<u>-</u>	<u>-</u>
Net decrease in cash and cash equivalents	(238,884)	(230,108)
Cash and cash equivalents, Beginning of Year	<u>1,462,277</u>	<u>1,692,385</u>
Cash and cash equivalents, End of Year	<u>\$ 1,223,393</u>	<u>\$ 1,462,277</u>

See accompanying notes to the financial statements.

LYNN SAGE BREAST CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 1 – NATURE OF ORGANIZATION

On January 1, 2021, the Lynn Sage Cancer Research Foundation merged with another not-for-profit, Lynn Sage Foundation (“LSF”). As a result of the merger, the surviving entity’s name was changed to Lynn Sage Breast Cancer Foundation (“the Foundation”) and the Foundation received \$816,662 of cash and assumed a \$125 other asset, \$4,907 of marketable securities, \$100,000 of grants payable for a total net asset change transfer of \$721,694.

Lynn Sage Breast Cancer Foundation formerly the Lynn Sage Cancer Research Foundation is an Illinois not-for-profit corporation incorporated on September 14, 1990 to raise funds and support research and medical education. Significant funding sources include contributions, gifts and grants, fundraising events and investment activities, to support breast cancer research and medical education through grants made to local research hospitals through awards to researchers fellowship grants and travel awards for symposiums.

The Lynn Sage Breast Cancer Foundation’s mission is to raise funds for research and education to prevent breast cancer and improve outcomes for individuals with breast cancer. Investments are directed locally within the Chicago area, but drive impact globally.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows:

Basis of Accounting

The financial statements of the Foundation have been prepared on the accrual basis of accounting in accordance with U.S. Generally Accepted Accounting Principles.

Accounting Policies

The Foundation follows accounting standards established by the Financial Accounting Standards Board (FASB) to ensure consistent reporting of financial condition, results of activities, and cash flows. Reference to Generally Accepted Accounting Principles (GAAP) in these footnotes is to the *FASB Accounting Standards Codification*, sometimes referred to as the Codification or ASC.

LYNN SAGE BREAST CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Financial Statement Presentation

The Foundation presents financial information pursuant to FASB Accounting Standards Codification *Not-for-Profit Entities: Presentation of Financial Statements (Subtopic 205)*, which establishes standards for external financial reporting by not-for-profit organizations and requires that resources be classified into distinct net asset categories according to externally (donor) imposed restrictions. In addition, the Foundation is required to present a statement of cash flows.

Net Assets Without Donor Restrictions – Net assets that are not subject to donor-imposed restrictions are net assets without donor restrictions. These assets include the revenues and expenses of the primary operations of the Foundation. Donor restricted contributions and grants whose restrictions are met in the same reporting period are reported as net assets without donor restrictions.

Net Assets With Donor Restrictions – Net assets subject to donor or grant-imposed stipulations that may or will be met either by actions of the Foundation and/or the passage of time are classified as net assets with donor restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions.

Cash and Cash Equivalents

The Foundation considers all short-term highly-liquid debt instruments with an original maturity of three months or less, when acquired, to be cash equivalents.

Investments

Investments are stated at fair value. Investments are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investments, it is at least reasonably possible that changes in values of investments will occur in the near term and that such changes could materially affect the amounts reported in the statements of financial position.

Interest income is recognized when earned. Dividend income is recognized on the ex-dividend date. Realized gains and losses are the differences between the proceeds received and the cost of investments sold and unrealized gains and losses are the differences between the fair value and cost of investments held.

LYNN SAGE BREAST CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Revenue Recognition – Contributions and Grants

The Foundation's support primarily consists of contributions. The Foundation recognizes contributions when cash, securities or other assets, an unconditional promise to give, is received. Conditional promises to give, that is, those with a measurable performance or other barrier and a right of return are not recognized until the conditions on which they depend have been substantially met.

Contributions and grants received are recorded as support within net assets without donor restrictions or net assets with donor restrictions, depending on the existence and/or nature of any donor-imposed restrictions.

Revenue from Contracts with Customers

The Foundation usually enters into contracts that have performance obligations. Special events revenue, which includes registration fees, ticket purchases, sponsorships and purchases of auction items or raffle tickets, is recorded as revenue when the event occurs, equal to the amounts received. If received in advance, the direct benefits to donors are deferred until the event occurs while the contribution portion, the excess paid over the direct benefit to donors, is recorded immediately.

Revenue Recognition – In-Kind Contributions

Donated services are recognized as contributions if the services (1) create or enhance nonfinancial assets or (2) require specialized skills, are performed by people with those skills, and would otherwise be purchased by the Foundation. Volunteers provide services that are not recognized as contributions in the financial statements since the revenue recognition criteria were not met. The Foundation records contributions of stock at fair value on the date of the gift.

The Foundation received donated goods comprised of gift cards and other prizes valued at \$56,590 for 2023 and \$1,600 2022. These amounts represent the face value of the gift cards and are used as prizes in the Foundation's special events. These amounts are reflected in the statements of activities as donated goods and services and as gifts and awards expense in the statements of functional expenses.

LYNN SAGE BREAST CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Revenue Recognition – In-Kind Contributions - Continued

Donated services are recognized as revenues at their estimated fair value when they create or enhance nonfinancial assets or they require specialized skills which would need to be purchased if they were not donated. The Foundation received \$2,275 of accounting services in 2023 and \$4,075 of accounting services in 2022. These services are valued based on prevailing hourly rates donated in the Foundation's principal market for the same kind of professional services. These amounts are reflected in the statements of activities as donated goods and services and as professional services expense in the statements of functional expenses.

These amounts are reflected in the statements of activities as donated goods and services and as audiovisual and professional fees expense in the statement of functional expenses.

A number of unpaid volunteers and members of the Board of Directors donate their time to ensure success of the Foundation's activities. The value of these services is not reflected in these financial statements since they do not meet the criteria for recognition under the FASB Codification topic related to accounting for contributions received and made.

Contributions and Grants Receivable

Contributions and grants receivable represents unconditional commitments made by donors. Contributions receivable that are expected to be collected in less than one year are reported at net realizable value. Contributions receivable that are expected to be collected in more than one year are recorded at fair value at the date of promise. That fair value is computed using a present value technique applied to anticipated cash flows. Amortization of the resulting discount is recognized as additional contribution revenue. Management determines a reserve for doubtful contributions receivable based on estimates of collectability with certain donors with past experience as well as a general reserve for the remaining amount.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

LYNN SAGE BREAST CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Tax-Exempt Status

The Foundation is a tax-exempt organization under Section 501(c) (3) of the Internal Revenue Code and follows the accounting standard on accounting for uncertainty in income taxes, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under this guidance the Foundation may recognize the tax benefits from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. Examples of tax positions include the tax-exempt status of the Foundation and various positions related to potential sources of unrelated business taxable income. There were no unrecognized tax benefits identified or recorded as liabilities for the reporting period presented in the financial statements. As of and for the year ended December 31, 2023, management has determined that there are no uncertain tax positions. The Foundation files Form 990 in the U.S. federal jurisdiction and the State of Illinois.

Fair Value of Financial Instruments

The carrying amounts of cash and cash equivalents, investments, accrued liabilities approximate fair value because of the short-term maturity of these financial instruments.

Functional Allocation of Expenses

The costs of program and supporting services activities have been summarized on a functional basis in the statements of activities. The statement of functional expenses presents the natural classification detail of expenses by function. Expenses directly attributable to a specific functional area of the Foundation are reported as expenses of those functional areas while indirect costs that benefit multiple functional areas have been allocated among various functional areas using a variety of cost allocation techniques such as square footage and time and effort. Such allocations are determined by management on an equitable basis.

Subsequent Events

The Foundation has evaluated subsequent events for potential recognition and/or disclosures through June 14, 2024, the date the financial statements were available to be issued.

LYNN SAGE BREAST CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 3 – CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Foundation to concentration of credit risk consist primarily of cash and cash equivalents and grants and contracts receivable.

The Foundation maintains its cash checking accounts, which from time to time may exceed the federally insured limits of \$250,000. The Foundation has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on cash and cash equivalents.

Investments are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with investments, it is at least reasonably possible that changes in the fair value of investments will occur in the near term and that such changes could materially affect the financial statements. Due to the market volatility in 2022, the Foundation experienced significant unrealized losses in the fair value of its portfolio.

NOTE 4 – FAIR VALUE MEASUREMENTS

The Foundation reports the fair value of its investments in accordance with the fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

The three levels of the fair value hierarchy are described as follows:

Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Foundation has the ability to access.

Level 2 Inputs to the valuation methodology include:

- quoted prices for similar assets or liabilities in active markets;
- quoted prices for identical or similar assets or liabilities in inactive markets;
- inputs other than quoted prices that are observable for the asset or liability;
- inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

LYNN SAGE BREAST CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 4 – FAIR VALUE MEASUREMENTS - Continued

Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The following table sets forth by level, within the fair value hierarchy, the Foundation's assets at fair value as of December 31, 2023:

	<u>Fair Value</u>	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Money Market Funds	\$ 31,998	\$ 31,998	\$ -	\$ -
Fixed Income Mutual Funds	1,268,947	1,268,947	-	-
Mutual Funds - Equity	3,120,573	3,120,573	-	-
Exchange Traded Products - Equity	526,942	526,942	-	-
	<u>\$ 4,948,460</u>	<u>\$ 4,948,460</u>	<u>\$ -</u>	<u>\$ -</u>

The following table sets forth by level, within the fair value hierarchy, the Foundation's assets at fair value as of December 31, 2022:

	<u>Fair Value</u>	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Money Market Funds	\$ 42,841	\$ 42,841	\$ -	\$ -
US Treasury Bills	872,973	872,973	-	-
Fixed Income Mutual Funds	255,934	255,934	-	-
Mutual Funds - Equity	1,773,605	1,773,605	-	-
International Equity Mutual Funds	541,352	541,352	-	-
Exchange Traded Products - Equity	368,242	368,242	-	-
	<u>\$ 3,854,947</u>	<u>\$ 3,854,947</u>	<u>\$ -</u>	<u>\$ -</u>

LYNN SAGE BREAST CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 5 – INVESTMENT RETURNS

Investment return as reported on the statements of activities includes:

	<u>2023</u>	<u>2022</u>
Realized gains, net	\$ 40,737	\$ (62,599)
Unrealized (loss)/gains, net	438,311	(475,164)
Dividends and interest income	136,833	130,950
Investment fees	<u>(24,219)</u>	<u>(30,169)</u>
Investments return, net	<u>\$ 591,662</u>	<u>\$ (436,982)</u>

NOTE 6– GRANT COMMITMENTS

In June 2020, the Foundation entered into an agreement with NMF for the naming rights of NMF’s principal breast cancer screening and diagnostic center, currently known as Lynn Sage Comprehensive Breast Center (the Center). In exchange for the naming rights, the Foundation has committed to support NMF, its other Affiliates, and Northwestern University’s Feinberg School of Medicine, in the amount of the larger of \$300,000 or 55% of the total gifts, grants, and contributions the Foundation raises each year, for a period of twenty-five years commencing January 1, 2020. This 55% is evaluated for review once every five years and once met, that period is no longer part of the calculation. After this period the Foundation has extension rights and first refusal rights to the naming of the Center, should another offer be made at that time to NMF by a third party, in which case the Foundation can retain the rights by meeting the terms of that offer. The entire period is divided into five consecutive five-year review periods. No later than three months after each review period, the Foundation has to demonstrate that it met these and other conditions specified in the agreement in order to retain the naming rights of the Center. The 55% primary support clause ceases to apply if the aggregate support during the 25-year period reaches \$20,000,000.

In December 2023, the Foundation entered into an agreement with the University of Chicago Medicine for the establishment of the Chicago Breast Cancer Research Consortium (the Consortium). The Foundation agreed to pay \$1,604,844 over a five year period commencing in early 2024 and extending until February 2028. Provided certain prespecified milestones are met each year, the Foundation will make annual payments to convene the Consortium which brings together the University of Chicago Medicine, Robert H Lurie Comprehensive Cancer Center at Northwestern and RUSH University for Healthy to run breast cancer clinical trials, share research findings and help support under-resourced patients to accessing these clinical trials.

LYNN SAGE BREAST CANCER FOUNDATION

NOTES TO FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 7 – LIQUIDITY AND AVAILABILITY

Financial assets available for general expenditures, that is, without donor or other restrictions limiting use, within one year as of December 31, 2023 and 2022 are:

	<u>2023</u>	<u>2022</u>
Financial assets:		
Cash and cash equivalents	\$ 1,430,928	\$ 1,664,152
Investments	4,948,460	3,854,947
Total financial assets	<u>6,379,388</u>	<u>5,519,099</u>
Amount available for general expenditures within one year	<u>\$ 6,379,388</u>	<u>\$ 5,519,099</u>

The Foundation has no net assets with donor restrictions, nor any board-designated net assets, so the entire amount of its liquid asset balance at December 31, 2023 and 2022 is available for use. The Foundation has sufficient liquid assets to meet more than one year of operating expenses.

NOTE 8 – RELATED PARTY TRANSACTIONS

During 2023, the Foundation's Board of Directors, their family foundations and founders of the Foundation donated \$230,140. During 2022, the Foundation's Board of Directors and Board member family foundations donated \$179,021.